Companies Progyny
Progyny (PGNY): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Progyny’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers16th pct.Of 19 peer CEOs
CEO pay, last three years
- $1,093,512FY2023
- $1,361,112FY2024
- $7,220,612FY2025
CEO total pay was $7,220,612 in fiscal 2025, up from $1,361,112 in fiscal 2024.
FY2025: salary $870,000 · bonus $0 · stock awards $3,499,980 · option awards $2,099,995
Executives and directors
Peter Anevski · CEOGeoffrey Clapp · Chief Product OfficerAllison Swartz · General CounselMark Livingston · CFOMelissa Cummings · COOCheryl Scott · Independent DirectorDebra Morris · Independent DirectorElizabeth Bierbower · Independent DirectorFred Cohen · Former director (through FY2025)Jeff Park · Lead Independent DirectorKevin Gordon · Independent DirectorLloyd Dean · Independent DirectorNorman Payson · Independent DirectorRoger Holstein · Independent Director
Frequently asked questions
Who was the highest-paid executive at Progyny in fiscal 2025?
As disclosed, Peter Anevski (Chief Executive Officer) was the highest-paid executive at Progyny in fiscal 2025, with total compensation of $7,220,612.
How does Progyny's chief executive pay compare to its disclosed peer group?
As disclosed, Peter Anevski's total compensation ranked at the 16th percentile of Progyny's disclosed peer group.
What is Progyny's CEO-to-median employee pay ratio?
As disclosed, Progyny's CEO-to-median employee pay ratio was 46:1.
How did shareholders vote on Progyny's executive compensation?
As disclosed, 94.12% of shareholders supported Progyny's executive compensation in the latest say-on-pay vote.
How much does Progyny spend in total on board compensation for fiscal 2025?
As disclosed, Progyny reported total board compensation of $1,358,969 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Peter Anevski | $870,000 | $0 | $3,499,980 | $2,099,995 | $736,890 | $0 | $13,747 | $7,220,612 |
| Chief Executive Officer | ||||||||
| Melissa Cummings | 429,546 | 0 | 1,149,993 | 689,988 | 386,550 | 0 | 39,084 | 2,695,161 |
| Chief Operating Officer | ||||||||
| Mark Livingston | 533,000 | 0 | 999,988 | 600,000 | 330,567 | 0 | 16,819 | 2,480,374 |
| Chief Financial Officer | ||||||||
| Geoffrey Clapp | 336,458 | 0 | 749,979 | 450,000 | 226,525 | 0 | 9,666 | 1,772,628 |
| Chief Product Officer | ||||||||
| Allison Swartz | 409,500 | 0 | 624,976 | 375,000 | 225,450 | 0 | 10,225 | 1,645,151 |
| Executive Vice President, General Counsel and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Peter Anevski | $7,220,612 | $1,361,112 | $1,093,512 | ↑ +5,859,500 |
| Melissa Cummings | 2,695,161 | — | — | — |
| Mark Livingston | 2,480,374 | 2,138,369 | 1,398,900 | ↑ +342,005 |
| Geoffrey Clapp | 1,772,628 | — | — | — |
| Allison Swartz | 1,645,151 | 1,932,128 | 546,222 | ↓ −286,977 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We have provided compensation packages that we view as fair and competitive relative to our peers and market data and that are designed to incentivize our executives to drive superior performance, as our ability to meet and exceed our business goals depends on the skills and contributions of each executive.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Semler Brossy |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Allison Swartz | RSU | 2025-03-03 | — | — | 22,727 | — | $499,994 |
| Peter Anevski | RSU | 2025-03-03 | — | — | 127,272 | — | 2,799,984 |
| Mark Livingston | RSU | 2025-03-03 | — | — | 36,363 | — | 799,986 |
| Geoffrey Clapp | OPTION | 2025-03-17 | — | — | 39,120 | — | 450,000 |
| Allison Swartz | OPTION | 2025-03-03 | — | — | 31,115 | — | 375,000 |
| Melissa Cummings | PSU | 2025-04-14 | 15,623 | 31,247 | — | 46,870 | 229,978 |
| Geoffrey Clapp | PSU | 2025-03-17 | 10,758 | 21,518 | — | 32,276 | 149,980 |
| Allison Swartz | PSU | 2025-03-03 | 8,521 | 17,042 | — | 25,563 | 124,975 |
| Mark Livingston | OPTION | 2025-03-03 | — | — | 49,783 | — | 600,000 |
| Peter Anevski | PSU | 2025-03-03 | 47,726 | 95,453 | — | 143,179 | 699,998 |
| Geoffrey Clapp | RSU | 2025-03-17 | — | — | 28,694 | — | 599,992 |
| Mark Livingston | PSU | 2025-03-03 | 13,635 | 27,272 | — | 40,907 | 199,995 |
| Peter Anevski | OPTION | 2025-03-03 | — | — | 174,239 | — | 2,099,995 |
| Melissa Cummings | RSU | 2025-04-14 | — | — | 41,667 | — | 920,000 |
| Melissa Cummings | OPTION | 2025-04-14 | — | — | 56,741 | — | 689,988 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Allison Swartz | $499,994 | $124,975 | $375,000 | 12.5% |
| Peter Anevski | 2,799,984 | 699,998 | 2,099,995 | 12.5% |
| Mark Livingston | 799,986 | 199,995 | 600,000 | 12.5% |
| Geoffrey Clapp | 599,992 | 149,980 | 450,000 | 12.5% |
| Melissa Cummings | 920,000 | 229,978 | 689,988 | 12.5% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mark Livingston | RSU | 2,185 | — | $56,111 |
| Mark Livingston | Option | 6,250 | 36.23 | — |
| Mark Livingston | RSU | 8,435 | — | 216,611 |
| Allison Swartz | RSU | 8,435 | — | 216,611 |
| Allison Swartz | RSU | 15,000 | — | 385,200 |
| Peter Anevski | RSU | 15,625 | — | 401,250 |
| Allison Swartz | RSU | 17,042 | — | 437,639 |
| Geoffrey Clapp | RSU | 21,518 | — | 552,582 |
| Allison Swartz | RSU | 22,727 | — | 583,629 |
| Mark Livingston | Option | 25,310 | 35.48 | — |
| Allison Swartz | Option | 25,310 | 35.48 | — |
| Mark Livingston | RSU | 27,272 | — | 700,345 |
| Geoffrey Clapp | RSU | 28,694 | — | 736,862 |
| Allison Swartz | Option | 31,115 | 22 | — |
| Melissa Cummings | RSU | 31,247 | — | 802,423 |
| Mark Livingston | RSU | 36,363 | — | 933,802 |
| Geoffrey Clapp | Option | 39,120 | 20.91 | — |
| Melissa Cummings | RSU | 41,667 | — | 1,070,009 |
| Allison Swartz | Option | 43,748 | 36.92 | — |
| Mark Livingston | Option | 49,783 | 22 | — |
| Melissa Cummings | Option | 56,741 | 22.08 | — |
| Mark Livingston | Option | 62,500 | 39.39 | — |
| Peter Anevski | Option | 62,500 | 50.35 | — |
| Peter Anevski | RSU | 95,453 | — | 2,451,233 |
| Peter Anevski | RSU | 127,272 | — | 3,268,345 |
| Peter Anevski | Option | 174,239 | 22 | — |
| Peter Anevski | Option | 200,000 | 39.39 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Kevin GordonIndependent · Audit (Chair) | $52,100 | $167,663 | $456,905 | $0 | $0 | $676,668 |
| Jeff ParkIndependent · Lead Independent Director · Compensation | 73,200 | 195,614 | 392,757 | 0 | 0 | 661,570 |
| Roger HolsteinIndependent · Compensation (Chair) · Nominating and Corporate Governance | 46,000 | 167,663 | 417,476 | 0 | 0 | 631,139 |
| Lloyd DeanIndependent · Audit · Nominating and Corporate Governance (Chair) | 44,500 | 167,663 | 378,025 | 0 | 0 | 590,188 |
| Debra MorrisIndependent · Audit · Newly elected | 38,400 | 0 | 509,561 | 0 | 0 | 547,961 |
| Elizabeth BierbowerIndependent · Compensation · Newly elected | 24,200 | 0 | 517,940 | 0 | 0 | 542,140 |
| Norman PaysonIndependent · Compensation | 42,900 | 139,733 | 338,585 | 0 | 0 | 521,218 |
| Cheryl ScottIndependent · Compensation · Nominating and Corporate Governance | 40,000 | 139,733 | 338,585 | 0 | 0 | 518,318 |
| Fred CohenIndependent · Not standing for re-election · Departed during FY | 19,600 | 0 | 0 | 0 | 0 | 19,600 |
| David SchlangerEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Peter AnevskiEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $139,750 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 10,000 / 7,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $380,900 |
| Equity awards (grant-date value) | $978,069 |
| All other compensation | $0 |
| Total cost of the board | $1,358,969 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Progyny as a peer
Companies that benchmark against PGNY
8 companies name PGNY as a compensation peer
The list of companies that name PGNY as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ALHC Alignment Healthcare, Inc.EVH Evolent Health, Inc.HQY HealthEquity, Inc.MASI Masimo CorporationNEO NeoGenomics, Inc.OMCL Omnicell, Inc.CRVL CorVel CorporationRGEN Repligen CorporationCERT Certara, Inc.HAE Haemonetics CorporationSHC Sotera Health CompanyQDEL QuidelOrtho CorporationRDNT RadNet, Inc.TDOC Teladoc Health, Inc.AZTA Azenta, Inc.ASTH Astrana Health, Inc.PRVA Privia Health Group, Inc.RCM R1 RCM Inc.PINC Premier, Inc.
Peer reciprocity
The companies Progyny names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Masimo Corporation | 2025 | Catherine Szyman | $850,048 | $16,388,693 | $1,399,998 | $1,130,000 | $19,797,140 |
| 2 | Astrana Health, Inc. | 2025 | Brandon Sim | 850,000 | 11,999,980 | 0 | 2,059,125 | 14,930,231 |
| 3 | Evolent Health, Inc. | 2025 | Seth Blackley | 867,068 | 12,699,086 | 0 | 0 | 14,240,154 |
| 4 | R1 RCM Inc. | 2023 | Lee Rivas | 900,000 | 12,240,021 | 0 | 1,015,200 | 14,159,376 |
| 5 | HealthEquity, Inc. | 2026 | Scott Cutler | 775,000 | 12,038,563 | 0 | 767,250 | 13,582,105 |
| 6 | RadNet, Inc. | 2025 | Howard Berger | 3,000,000 | 8,999,966 | 0 | 0 | 12,087,934 |
| 7 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 8 | Premier, Inc. | 2024 | Michael Alkire | 1,095,876 | 8,500,039 | 0 | 1,800,150 | 11,806,381 |
| 9 | Alignment Healthcare, Inc. | 2025 | John Kao | 833,654 | 8,500,014 | 0 | 1,944,495 | 11,278,583 |
| 10 | QuidelOrtho Corporation | 2025 | Brian Blaser | 1,000,000 | 8,965,822 | 0 | 1,274,500 | 11,255,782 |
| 11 | Teladoc Health, Inc. | 2025 | Charles Divita, III | 800,000 | 9,699,996 | 0 | 584,000 | 11,202,996 |
| 12 | Sotera Health Company | 2025 | Michael Petras | 1,130,699 | 8,022,400 | 0 | 1,484,890 | 10,656,063 |
| 13 | Privia Health Group, Inc. | 2025 | Parth Mehrotra | 650,000 | 8,588,373 | 0 | 1,218,750 | 10,472,698 |
| 14 | Azenta, Inc. | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 15 | NeoGenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 16 | Omnicell, Inc. | 2025 | Randall Lipps | 846,891 | 5,219,576 | 0 | 1,411,485 | 7,531,852 |
| 17 | Progyny | 2025 | Peter Anevski | 870,000 | 3,499,980 | 2,099,995 | 736,890 | 7,220,612 |
| 18 | Certara, Inc. | 2025 | William Feehery | 795,675 | 4,927,502 | 0 | 747,935 | 6,491,387 |
| 19 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 20 | CorVel Corporation | 2026 | Michael Combs | 679,327 | 0 | 101,716 | 498,809 | 1,285,043 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Progyny | 85% | RSU 40 · Options 30 · PSU 30 | No | Semler Brossy |
| Alignment Healthcare, Inc. | 200% | not disclosed | No | FW Cook |
| Astrana Health, Inc. | 193.8% | PSU 67 · RSU 33 | No | Pearl Meyer |
| Azenta, Inc. | not disclosed | PSU 50 · RSU 50 | Yes — Relative TSR (rTSR) | Pearl Meyer |
| Certara, Inc. | 94% | PSU 60 · RSU 40 | Yes — annualized total stockholder return (ATSR) | Meridian Compensation Partners |
| CorVel Corporation | CEO: 75%, EVP Risk: 61%, CIO: 49%, VP Accounting: 28%% | not disclosed | No | not disclosed |
| Evolent Health, Inc. | 75% | PSU 70 · RSU 30 | No | Exequity |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| HealthEquity, Inc. | 99% | PSU 60 · RSU 40 | Yes | Semler Brossy |
| Masimo Corporation | not disclosed | not disclosed | not disclosed | FW Cook |
| NeoGenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| Omnicell, Inc. | 133.3% | RSU 50 · PSU 50 | No | Exequity |
| Premier, Inc. | 109.1% | PSU 60 · RSU 40 | No | Mercer |
| Privia Health Group, Inc. | 150% | PSU 60 · RSU 40 | No | Korn Ferry (through September 2025), WTW (starting September 2025) |
| QuidelOrtho Corporation | not disclosed | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) | Compensia |
| R1 RCM Inc. | 94% | PSU 75 · RSU 25 | No | SullivanCotter |
| RadNet, Inc. | not disclosed | RSU 100 | No | Pearl Meyer |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Sotera Health Company | 103% | PSU 40 · RSU 40 · Other 20 | No | Exequity, LLP |
| Teladoc Health, Inc. | 73% | RSU 50 · PSU 50 | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 61,804,376 | 3,604,955 | 253,817 | 94.12% | Passed |
| 2025 | 2025-05-22 | 24,399,909 | 43,948,036 | 91,631 | 35.65% | Failed |
| 2024 | 2024-05-23 | 82,109,794 | 1,914,294 | 134,521 | 97.57% | Passed |
| 2023 | 2023-05-24 | 27,068,098 | 55,767,673 | 63,987 | 32.65% | Failed |
| 2022 | 2022-05-25 | 77,734,833 | 1,011,237 | 51,041 | 98.65% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-21 | 94.12%a |
| 2025 | 2025-05-22 | 35.65%b |
| 2024 | 2024-05-23 | 97.57%c |
a. Approved under the standard stated in the filing — “Abstentions will be counted as present for purposes of this vote, and therefore will have the same effect as an " AGAINST " vote.”.
b. Approved under the standard stated in the filing — “Abstentions will be counted as present for purposes of this vote, and therefore will have the same effect as an " AGAINST " vote.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted as present for purposes of this vote, and therefore will have the same effect as an " AGAINST " vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 46 : 1 |
|---|---|
| CEO total compensation | $7,220,612 |
| Median employee compensation | $156,677 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Melissa Cummings | Chief Operating Officer | 2026-04-14 | D | 4,172 | $17 | $70,841 | Common | Form 4 ↗ |
| Melissa Cummings | Chief Operating Officer | 2026-05-19 | D | 9,578 | 25 | 239,450 | Common | Form 4 ↗ |
| Mark Livingston | Chief Financial Officer | 2026-05-20 | D | 8,275 | 26 | 211,013 | Common | Form 4 ↗ |
| Cheryl Scott | Director | 2026-05-21 | A | 5,660 | 0 | 0 | RSU | Form 4 ↗ |
| Debra Morris | Director | 2026-05-21 | A | 3,203 | 12 | 40,005 | Derivative, Class A Common | Form 4 ↗ |
| Cheryl Scott | Director | 2026-05-21 | A | 27,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Norman Payson | Director | 2026-05-21 | A | 3,203 | 12 | 40,005 | Derivative, Class A Common | Form 4 ↗ |
| Jeff Park | Director | 2026-05-21 | A | 31,458 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roger Holstein | Director | 2026-05-21 | A | 29,289 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roger Holstein | Director | 2026-05-21 | A | 4,003 | 12 | 49,997 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-05-21 | A | 6,792 | 0 | 0 | RSU | Form 4 ↗ |
| Lloyd Dean | Director | 2026-05-21 | A | 6,792 | 0 | 0 | RSU | Form 4 ↗ |
| Elizabeth Bierbower | Director | 2026-05-21 | A | 3,203 | 12 | 40,005 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Bierbower | Director | 2026-05-21 | A | 5,660 | 0 | 0 | RSU | Form 4 ↗ |
| Debra Morris | Director | 2026-05-21 | A | 27,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Norman Payson | Director | 2026-05-21 | A | 27,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Norman Payson | Director | 2026-05-21 | A | 5,660 | 0 | 0 | RSU | Form 4 ↗ |
| Jeff Park | Director | 2026-05-21 | A | 7,924 | 0 | 0 | RSU | Form 4 ↗ |
| Elizabeth Bierbower | Director | 2026-05-21 | A | 27,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-05-21 | A | 30,373 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeff Park | Director | 2026-05-21 | A | 5,205 | 12 | 65,010 | Derivative, Class A Common | Form 4 ↗ |
| Debra Morris | Director | 2026-05-21 | A | 5,660 | 0 | 0 | RSU | Form 4 ↗ |
| Roger Holstein | Director | 2026-05-21 | A | 6,792 | 0 | 0 | RSU | Form 4 ↗ |
| Lloyd Dean | Director | 2026-05-21 | A | 28,203 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-05-27 | A | 2,526 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-05-27 | D | 2,526 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-05-27 | D | 5,500 | 25 | 137,445 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-05-28 | D | 2,398 | 25 | 61,053 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-05-28 | D | 1,352 | 25 | 34,449 | Common | Form 4 ↗ |
| Cheryl Scott | Director | 2026-06-01 | D | 14,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cheryl Scott | Director | 2026-06-01 | A | 14,667 | 13 | 190,671 | Common | Form 4 ↗ |
| Cheryl Scott | Director | 2026-06-01 | D | 7,439 | 26 | 196,278 | Common | Form 4 ↗ |
| Cheryl Scott | Director | 2026-06-01 | D | 7,228 | 26 | 190,675 | Common | Form 4 ↗ |
| Geoffrey Clapp | Chief Product Officer | 2026-06-02 | D | 1,530 | 26 | 39,137 | Common | Form 4 ↗ |
| Geoffrey Clapp | Chief Product Officer | 2026-06-02 | D | 12,909 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Livingston | Chief Financial Officer | 2026-06-02 | D | 158 | 26 | 4,140 | Common | Form 4 ↗ |
| Geoffrey Clapp | Chief Product Officer | 2026-06-02 | D | 11,379 | 26 | 290,620 | Common | Form 4 ↗ |
| Mark Livingston | Chief Financial Officer | 2026-06-02 | D | 279 | 26 | 7,310 | Common | Form 4 ↗ |
| Geoffrey Clapp | Chief Product Officer | 2026-06-02 | A | 12,909 | 21 | 269,927 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-06-03 | D | 676 | 25 | 16,981 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-06-03 | D | 1,199 | 25 | 29,999 | Common | Form 4 ↗ |
| Mark Livingston | Chief Financial Officer | 2026-06-03 | D | 1,082 | 25 | 27,180 | Common | Form 4 ↗ |
| Peter Anevski | Director | 2026-06-03 | D | 5,361 | 25 | 134,668 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-06-04 | D | 599 | 25 | 15,023 | Common | Form 4 ↗ |
| Mark Livingston | Chief Financial Officer | 2026-06-04 | D | 599 | 26 | 15,275 | Common | Form 4 ↗ |
| Mark Livingston | Chief Financial Officer | 2026-06-04 | D | 339 | 25 | 8,472 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-06-04 | D | 339 | 25 | 8,472 | Common | Form 4 ↗ |
| Mark Livingston | Chief Financial Officer | 2026-06-04 | D | 1,918 | 26 | 48,909 | Common | Form 4 ↗ |
| Geoffrey Clapp | Chief Product Officer | 2026-06-17 | D | 819 | 27 | 21,785 | Common | Form 4 ↗ |
| Melissa Cummings | Chief Operating Officer | 2026-07-14 | D | 2,244 | 32 | 70,910 | Common | Form 4 ↗ |
| Melissa Cummings | Chief Operating Officer | 2026-07-14 | D | 1,193 | 32 | 38,152 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-08-28 | D | 1,352 | 26 | 34,963 | Common | Form 4 ↗ |
| Mark Livingston | Chief Financial Officer | 2026-09-02 | D | 224 | 26 | 5,748 | Common | Form 4 ↗ |
| Peter Anevski | Director | 2026-09-03 | D | 5,361 | 26 | 140,941 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-09-03 | D | 828 | 26 | 21,768 | Common | Form 4 ↗ |
| Mark Livingston | Chief Financial Officer | 2026-09-03 | D | 1,532 | 26 | 40,276 | Common | Form 4 ↗ |
| Mark Livingston | Chief Financial Officer | 2026-09-04 | D | 479 | 27 | 12,746 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-09-04 | D | 479 | 27 | 12,746 | Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-09-10 | D | 11,500 | 27 | 311,858 | Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-09-10 | D | 10,500 | 27 | 286,020 | Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-09-10 | D | 11,500 | 28 | 321,358 | Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-09-10 | D | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-09-10 | D | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-09-10 | A | 22,000 | 13 | 286,000 | Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-09-10 | D | 10,500 | 27 | 286,020 | Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-09-10 | A | 22,000 | 13 | 286,000 | Common | Form 4 ↗ |
| Geoffrey Clapp | Chief Product Officer | 2026-09-17 | D | 819 | 27 | 22,424 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-09-23 | D | 3,903 | 26 | 101,868 | Common | Form 4 ↗ |
| Melissa Cummings | Chief Operating Officer | 2026-10-14 | D | 1,879 | 28 | 52,612 | Common | Form 4 ↗ |
| Melissa Cummings | Chief Operating Officer | 2026-10-14 | D | 1,559 | 27 | 42,701 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (129 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Peter Anevski. DEF 14A, filed 2026-04-10. Section “2025 Summary Compensation Table” · page 34. As printed: 7,220,612. View filing ↗
- Section 01, Melissa Cummings. DEF 14A, filed 2026-04-10. Section “2025 Summary Compensation Table”. As printed: 2,695,161. View filing ↗
- Section 01, Mark Livingston. DEF 14A, filed 2026-04-10. Section “2025 Summary Compensation Table”. As printed: 2,480,374. View filing ↗
- Section 01, Geoffrey Clapp. DEF 14A, filed 2026-04-10. Section “2025 Summary Compensation Table”. As printed: 1,772,628. View filing ↗
- Section 01, Allison Swartz. DEF 14A, filed 2026-04-10. Section “2025 Summary Compensation Table”. As printed: 1,645,151. View filing ↗
- Section 03, Allison Swartz RSU. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Peter Anevski RSU. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Livingston RSU. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Geoffrey Clapp OPTION. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Allison Swartz OPTION. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Melissa Cummings PSU. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Geoffrey Clapp PSU. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Allison Swartz PSU. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Livingston OPTION. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Peter Anevski PSU. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Geoffrey Clapp RSU. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Livingston PSU. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Peter Anevski OPTION. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Melissa Cummings RSU. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Melissa Cummings OPTION. DEF 14A, filed 2026-04-10. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-10. Section “CEO Pay Ratio”. As printed: 46 : 1. View filing ↗
- Section 08, Kevin Gordon. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 676,668. View filing ↗
- Section 08, Jeff Park. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 661,570. View filing ↗
- Section 08, Roger Holstein. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 631,139. View filing ↗
- Section 08, Lloyd Dean. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 590,188. View filing ↗
- Section 08, Debra Morris. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 547,961. View filing ↗
- Section 08, Elizabeth Bierbower. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 542,140. View filing ↗
- Section 08, Norman Payson. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 521,218. View filing ↗
- Section 08, Cheryl Scott. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 518,318. View filing ↗
- Section 08, Fred Cohen. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 19,600. View filing ↗
- Section 08, David Schlanger. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Peter Anevski. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Melissa Cummings 2026-04-14. Form 4, filed 2026-04-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melissa Cummings 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Livingston 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl Scott 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Morris 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl Scott 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Norman Payson 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Park 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roger Holstein 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roger Holstein 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lloyd Dean 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Bierbower 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Bierbower 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Morris 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Norman Payson 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Norman Payson 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Park 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Bierbower 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Park 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Morris 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roger Holstein 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lloyd Dean 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Swartz 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Swartz 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl Scott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl Scott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl Scott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl Scott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoffrey Clapp 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoffrey Clapp 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Livingston 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoffrey Clapp 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Livingston 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoffrey Clapp 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Swartz 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Swartz 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Livingston 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Anevski 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Swartz 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Livingston 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Livingston 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Swartz 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Livingston 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoffrey Clapp 2026-06-17. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melissa Cummings 2026-07-14. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melissa Cummings 2026-07-14. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Swartz 2026-08-28. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Livingston 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Anevski 2026-09-03. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Swartz 2026-09-03. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Livingston 2026-09-03. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Livingston 2026-09-04. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Swartz 2026-09-04. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-09-10. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-09-10. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-09-10. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-09-10. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Gordon 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geoffrey Clapp 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Swartz 2026-09-23. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melissa Cummings 2026-10-14. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melissa Cummings 2026-10-14. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-27. Item 5.07 · say-on-pay result. As reported: 94.12% (votes for as printed: 61,804,376). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-28. Item 5.07 · say-on-pay result. As reported: 35.65% (votes for as printed: 24,399,909). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-29. Item 5.07 · say-on-pay result. As reported: 97.57% (votes for as printed: 82,109,794). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 380,900 + equity 978,069 + all other 0 = 1,358,969, summed across the director compensation table rows.
- Masimo Corporation, Section 10b CEO total. 10-K/A, filed 2026-05-01. CEO total compensation as printed in Masimo Corporation's own proxy. As printed: 19,797,140. View filing ↗
- Astrana Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Astrana Health, Inc.'s own proxy. As printed: 14,930,231. View filing ↗
- Evolent Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Evolent Health, Inc.'s own proxy. As printed: 14,240,154. View filing ↗
- R1 RCM Inc., Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in R1 RCM Inc.'s own proxy. As printed: 14,159,376. View filing ↗
- HealthEquity, Inc., Section 10b CEO total. DEF 14A, filed 2026-05-13. CEO total compensation as printed in HealthEquity, Inc.'s own proxy. As printed: 13,582,105. View filing ↗
- RadNet, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in RadNet, Inc.'s own proxy. As printed: 12,087,934. View filing ↗
- Haemonetics Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. View filing ↗
- Premier, Inc., Section 10b CEO total. DEF 14A, filed 2024-10-21. CEO total compensation as printed in Premier, Inc.'s own proxy. As printed: 11,806,381. View filing ↗
- Alignment Healthcare, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Alignment Healthcare, Inc.'s own proxy. As printed: 11,278,583. View filing ↗
- QuidelOrtho Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in QuidelOrtho Corporation's own proxy. As printed: 11,255,782. View filing ↗
- Teladoc Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Teladoc Health, Inc.'s own proxy. As printed: 11,202,996. View filing ↗
- Sotera Health Company, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Sotera Health Company's own proxy. As printed: 10,656,063. View filing ↗
- Privia Health Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Privia Health Group, Inc.'s own proxy. As printed: 10,472,698. View filing ↗
- Azenta, Inc., Section 10b CEO total. DEF 14A, filed 2025-12-18. CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. View filing ↗
- NeoGenomics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. View filing ↗
- Omnicell, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Omnicell, Inc.'s own proxy. As printed: 7,531,852. View filing ↗
- Progyny (subject), Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Progyny's own proxy. As printed: 7,220,612. View filing ↗
- Certara, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Certara, Inc.'s own proxy. As printed: 6,491,387. View filing ↗
- Repligen Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. View filing ↗
- CorVel Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-26. CEO total compensation as printed in CorVel Corporation's own proxy. As printed: 1,285,043. View filing ↗
- Section 10a, HealthEquity, Inc. reciprocity. DEF 14A. HealthEquity, Inc. names Progyny in its own disclosed peer group (read from its most recent proxy). View filing ↗